SL
Silence Therapeutics plc
SLN · NASDAQ
$12.46 -4.96% (-$0.65)
1M -13.17%
Market Cap $588.5M
P/E Ratio -
Div. Yield -
ROE 106.90%
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/B 15.30x
P/S 958.07x
EV/FFO N/A
Growth
22 /100
Declining Book val. growth 41.33%
Rev. growth 68.36%
FCF growth N/A
Profitability
20 /100
Weak Net margin 9,755.61%
Op. margin 11,003.00%
FCF margin 6,893.22%
Quality
0 /100
Poor ROE 106.90%
ROA 56.32%
Asset turnover 0.01x
Debt
33 /100
High Current ratio 7.42x
Debt/Equity -0.00x
Net debt/EBITDA N/A
Stability
41 /100
Moderate Rev. volatility 90.95%
EPS volatility 11.98%
Profitable years 0
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na SLN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Iain Gladstone Ross
Employees
88
Headquarters
London
Nadcházející události
05 LIS
Earnings
Upcoming earnings report